Autran Biotech was established, starting with the development, production and sales of generic drugs.
It thrives relying on Korean market.
Obtained the general agent of Entecavir for Japan and Korea markets from Bright-Gene Bio-Medical Technology Co., Ltd.
Acquired the general agent of Donepezil Hydrochloride Intermediate from Jinan Chenghui Shuangda Chemical Co., Ltd. for Korean market.
Acquired the general agent of GPC market in Japan and Korea of Hunan Warrant Chiral Pharmaceutical Co., Ltd.
Obtained the general agent of Micafungin Sodium in Japan and Korea of BrightGene Bio-Medical Technology Co., Ltd.
Successfully launched the research and development project of Autran Prunella Compound Extract, the production base was established in Hunan Warrant Chiral Pharmaceutical Co., Ltd., and became the sales sovereign of the product.
Korea Branch Autran Pharm Korea Co., Ltd. was established.
The company has signed an exclusive agency agreement with Ildong Bioscience Co.,Ltd., to become the sole agent for its probiotic products in China.
Acquired the general agent of Bovine liver extract from Hangzhou Huajin Pharmaceutical Co., Ltd. for Korean market.
Acquired the general agent of Orlistat from Shandong New Time Pharmaceutical Co., LTD. for Korean market.
The generic API (Micafungin Sodium) was registered successfully in Japanese market.
SINSIN BIOPHARMATIS CO.,LTD was established as branch.
The first generic API (Micafungin Sodium) was registered successfully in Korean market.
Signed the strategic agreement with Chongqing ChanghuaEnlong Pharmaceutical Technology Co., Ltd.
Signed Tadalafil project with CMG Pharmaceutical Co.,Ltd., Chongqing Zein health、Chongqing en Chuang Medical Management Co., Ltd.
Acquired the exclusive agent agreement of Biotin from Zhejiang Shengda
Bio-Pharm Co., Ltd. for Japanese and Korean market.
Acquired the exclusive agency agreement of DL - camphor from Wuzhou huangpu chemical pharmaceutical co. LTD for Korean market
Acquired the exclusive agent agreement of Fish Oil from Shandong Yuwang Pharmaceutical Co., Ltd. for Korean market and the customer protection agreement in Japanese market.
Acquired the exclusive agency agreement of Iodic Contrast Medium from Brother Enterpriese Holding Co.Ltd for Korean market.
Obtain the exclusive agency of VIwit pharmaceutical co., LTD. Mirabegron for the Korean market.
Obtain the exclusive agency of Weihai Disu pharmaceutical co., LTD. Rivaroxaban for the Korean market.
Liraglutide Korea Customer Protection Agreement, Hangzhou Jiuyuan Genetic Engineering Co., Ltd.
Exclusive Agency Agreement for Polymyxin E Sodium Mesylate, Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.
Agency Agreement for Import of Tuloterol Patch from Japan